<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="114" measure-type="hr" measure-number="4976" measure-id="id114hr4976" originChamber="HOUSE" orig-publish-date="2016-04-18" update-date="2016-06-13">
<title>Opioid Review Modernization Act of 2016</title>
<summary summary-id="id114hr4976v81" currentChamber="HOUSE" update-date="2016-06-13">
<action-date>2016-05-11</action-date>
<action-desc>Passed House without amendment</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The expanded summary of the House reported version is repeated here.)</p> <p><b>Opioid Review Modernization Act of 2016</b></p> <p>(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refer new drug applications for opioids (drugs with effects similar to opium, such as certain pain medications) to an advisory committee before approval, unless the FDA finds that such a referral is scientifically unnecessary and not in the interest of protecting and promoting public health and the FDA notifies Congress of its rationale.</p> <p>The FDA must convene an advisory committee on labeling opioids for pediatric use before approving any such labeling.</p> <p>(Sec. 3) As part of its evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, the FDA must develop recommendations regarding education programs for prescribers of opioids.</p> (Sec. 4) The FDA must finalize the draft guidance entitled &quot;General Principals for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products.&quot;]]></summary-text>
</summary>
<summary summary-id="id114hr4976v79" currentChamber="HOUSE" update-date="2016-06-13">
<action-date>2016-05-10</action-date>
<action-desc>Reported to House without amendment</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)</p> <p><b>Opioid Review Modernization Act of 2016</b></p> <p>(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refer new drug applications for opioids (drugs with effects similar to opium, such as certain pain medications) to an advisory committee before approval, unless the FDA finds that such a referral is scientifically unnecessary and not in the interest of protecting and promoting public health and the FDA notifies Congress of its rationale.</p> <p>The FDA must convene an advisory committee on labeling opioids for pediatric use before approving any such labeling.</p> <p>(Sec. 3) As part of its evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, the FDA must develop recommendations regarding education programs for prescribers of opioids.</p> (Sec. 4) The FDA must finalize the draft guidance entitled &quot;General Principals for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products.&quot;]]></summary-text>
</summary>
<summary summary-id="id114hr4976v00" currentChamber="HOUSE" update-date="2016-05-09">
<action-date>2016-04-18</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p><b>Opioid Review Modernization Act of 2016</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to refer new drug applications for opioids (drugs with effects similar to opium, such as certain pain medications) to an advisory committee before approval, unless the FDA finds that such a referral is scientifically unnecessary and not in the interest of protecting and promoting public health and the FDA notifies Congress of its rationale.</p> <p>The FDA must convene an advisory committee on labeling opioids for pediatric use before approving any such labeling.</p> <p>As part of its evaluation of the Extended-Release/Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy, the FDA must develop recommendations regarding education programs for prescribers of opioids.</p> The FDA must finalize the draft guidance entitled &quot;General Principals for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products.&quot;]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
